TSO3 Inc has a 181 per cent upside, says Echelon Wealth

Jan 10 18:01 2019 Print This Article

Look for medical tech company TSO3 (TSO3 Stock Quote, Chart TSX:TOS) to become EBITDA-positive this year, says Echelon Wealth Partners analyst Douglas W. Loe, who in a client update on Wednesday reiterated his “Buy” rating and C$1.80 price target for TSO3, representing a projected return of 181 per cent at the time of publication. Loe […]

The post TSO3 Inc has a 181 per cent upside, says Echelon Wealth appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Motley Fool on Fiserv/First Data

The Motley Fool takes a deep dive on the merger: The new Fiserv Management of the two companies expects the acquisition to lead to $900 million in cost savings and $500 million in revenue synergies over a five-year period, and generate $4 billion in free cash flow by 2022. Let’s tackle these iss ...

Morning News: January 22, 2019

Stocks Slide After the IMF Cut Its Forecast for Global Growth Amid Mounting Concerns About the US-China Trade War Chilling Davos: A Bleak Warning on Global Division and Debt The Stock Market’s On-Again, Off-Again Relationship With Trump Powell’s Game Plan CEOs Are Good at Predicting Economic Tr ...

Kinaxis gets thumbs up from Laurentian Bank for Novartis win

A big customer win for Kinaxis (Kinaxis Stock Quote, Chart TSX:KXS) has earned praise from Laurentian Bank Securities analyst Nick Agostino. This morning, Kinaxis announced that Swiss pharma giant Novartis had chosen Kinaxis’s RapidResponse as its new supply chain planning system. “Novartis pro ...

Take a pass on Constellation Software, Industrial Alliance says

Even with its share price pullback and strong top and bottom line growth, Constellation Software (Constellation Software Stock Quote, Chart TSX:CSU) is still a pricey stock, says Blair Abernethy of Industrial Alliance Securities, who ahead of the company’s fiscal fourth quarter financials reitera ...

My TFSA Update December 2018

Image Credit: cornfield / Shutterstock.com   In this series, I (Jin Choi) talk about my journey of investing in my TFSA account. If you want to know what a TFSA is, I recommend you read my free book.   December Results: Down 5.1% At the end of December, I had $37,045 in my TFSA account, which ...

50 top Canadian stock picks for 2019 as chosen by the pros

Last year was a rough one for investors, with markets turning in their worst performance in 10 years. And volatility promises to be a constant challenge for investors in 2019. But where there is upheaval there is also opportunity, and the drop in valuations means there are potential bargains to be ...

Canopy Growth and Cronos Group will “dominate” the global market, CIBC says

Canadian banks are getting behind cannabis, with the latest effort coming from CIBC, which Thursday launched coverage of the sector, issuing “Outperform” ratings to industry heavyweights Canopy Growth Corp. (Canopy Growth Stock Quote, Chart TSX:WEED, NYSE:CGC) and Cronos Group (Cronos Group Sto ...

Profound Medical still has a huge upside, says Paradigm Capital

Paradigm Capital analyst Rahul Sarugaser is calling 2019 a breakout year for medical device company Profound Medical (Profound Medical Stock Quote, Chart TSX:PRN), who’s recent rally is only the beginning, the analyst says. “PRN’s stock price has risen from its low of $0.43 on December 20, 20 ...

Canopy Growth Corp has truly global ambitions, CEO Bruce Linton says

Canopy Growth Corp’s (Canopy Growth Corp Stock Quote, Chart TSX:WEED, NYSE:CGC) new expansion into the US has gotten a lot of attention from investors this week but for CEO and co-founder Bruce Linton, it’s all part of his plan to bring his Canadian-tested business model to the rest of the worl ...

Cannabis in the news January 16, 2019

Read Next Article → News on cannabis stocks and on developments in the industry haven’t let up in today’s volatile markets. Here are the stories that we believe will mean most to you as a Canadian investor. 1. Canopy Growth Corp. is making a federally-sanctioned move into the U.S. with its pl ...